AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of 15th May, 2019 (the “Amendment Date”), and effective as of the Effective Date, is made and entered into by and between The Rockefeller University, a New York not-for-profit education corporation, with a principal place of business at 1230 York Avenue, New York, NY 10065 (“Rockefeller”, also referred to herein as “Licensor”) and Vir Biotechnology, Inc. a Delaware corporation, with a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (referred to herein as “Licensee”).
ContractVir Biotechnology, Inc. • August 7th, 2019 • Biological products, (no disgnostic substances)
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
COLLABORATION AND LICENSE AGREEMENT by and among Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. Dated as of October 16, 2017Collaboration and License Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 16, 2017 (the “Effective Date”), by and among Vir Biotechnology, Inc., a Delaware corporation, having a place of business at 499 Illinois Street, San Francisco, CA 94158 (“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 300 Third Street, 3rd Floor, Cambridge, Massachusetts 02142, USA (“Alnylam”).
COLLABORATION, OPTION, AND LICENSE AGREEMENTCertain • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This COLLABORATION, OPTION, AND LICENSE AGREEMENT (this “Agreement”) is made as of 23 May, 2018 (the “Execution Date), and effective as of the Effective Date (as defined herein) by and between VIR BIOTECHNOLOGY, INC., a Delaware corporation, having a place of business at 499 Illinois Street, San Francisco, California 94158, United States of America (“Vir”), BIIG THERAPEUTICS LIMITED, DBA BRII BIOSCIENCES LIMITED, a corporation organized under the laws of the Cayman Islands, having a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1—1205 Cayman Islands (“Parent”), and BRII BIOSCIENCES OFFSHORE LIMITED a corporation to be established by Parent in accordance with Section 17.1 of this Agreement and organized under the laws of the Cayman Islands, having a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1—1205 Cayman Islands (“Brii Bi
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.Letter Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Washington
This letter agreement (including all appendices hereto, this “Letter Agreement”) is entered into as of December 23, 2016 (the “Effective Date”) by and between the Bill & Melinda Gates Foundation (the “Foundation”), a Washington charitable trust that is a tax-exempt private foundation, and Vir Biotechnology, Inc., a Delaware corporation (the “Company”), in connection with the investment by the Foundation of twenty million dollars ($20,000,000.00) (the “Foundation Investment”) in the Company through the purchase of (i) ten million dollars ($10,000,000) of shares of Series A-1 Preferred Stock, par value $0.001, of the Company (the “Series A-1 Shares”) at a purchase price of [***] per share and (ii) ten million dollars ($10,000,000) of shares of Series B Preferred Stock, par value $0.001, of the Company (the “Series B Shares” and, together with the Series A-1 Shares, the “Shares”) at a purchase price of [***] per share. The Foundation shall purchase the Shares pursuant to and in accordance
EXCLUSIVE LICENSE AGREEMENT AMENDED AND RESTATEDExclusive License Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Agreement, originally effective as of July 28, 2004, and as amended and restated December 16, 2011, is by and between the institute for Research in Biomedicine (“IRB”), with an address at Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland and Humabs Holding GmbH, with an address at c/o Risk-Consult AG, Poststrasse 22, 6300 Zug, Switzerland (“Humabs” or “Licensee”).
AMENDMENT 4 TO SUB-LICENCE AND COLLABORATION AGREEMENTSub-Licence and Collaboration Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Fourth Amendment (the “Amendment”) to the Sub-Licence and Collaboration Agreement dated 20 March 2012, as amended (the “2012 Agreement”) is entered into and effective as of the last date of signature (the “Amendment Effective Date”), by and between:
AMENDMENT TO LICENSE AGREEMENT Humabs Holding GmbH And The Institute For Research in Biomedicine February 10, 2012License Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
Whereas, Humabs Holding GmbH (“Humabs”) and the Institute for Research in Biodmedicine (“IRB”) are parties to a license agreement dated as of December 16, 2011 (the “License Agreement”).
AMENDMENT NO. 3 TO SUB-LICENCE AND COLLABORATION AGREEMENTSub-Licence and Collaboration Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 3 to Sub-Licence and Collaboration Agreement (“Amendment No.3”) is effective as of 31 December 2015 (the “Amendment No.3 Effective Date”) by and between MedImmune, LLC, a Delaware limited liability company with a place of business at One MedImmune Way, Gaithersburg, MD20878, United States (“MedImmune”) and Humabs BioMed SA, a limited company organized under the laws of Switzerland having its head office at Via Mirasloe 1, Bellinzona CH-6500, Switzerland ( “Humabs”). MedImmune and Humabs are each referred to herein as a “Party” and collectively as the “Parties”.
REVISED AND RESTATED MASTER EXCLUSIVE LICENSE AGREEMENT BETWEEN OHSU AND TOMEGAVAX, INC. APPENDIX A: COMMERCIAL DEVELOPMENT PLAN APPENDIX B: ANNUAL UPDATE TO COMMERCIAL DEVELOPMENT PLAN APPENDIX C: QUARTERLY REPORT APPENDIX D: BUSINESS PLAN APPENDIX...Master Exclusive License Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • Oregon
This Revised and Restated Master Exclusive License Agreement (this “Agreement”), is between the Oregon Health & Science University, having offices at 0690 SW Bancroft Street, Portland, Oregon 97239 (“OHSU”), and TomegaVax, Inc., having offices at 12909 SW 68th Parkway, Suite 430, Portland, Oregon 97223-8387 (“Licensee”). OHSU and Licensee are herein referred to each as a “Party” and collectively as the “Parties.” This Agreement shall replace in its entirety the Master Exclusive License Agreement between the Parties, dated and effective as of June 22, 2012 (the “Effective Date”). The Effective Date for this Agreement shall remain the same as for the Master Exclusive License Agreement.
EXCLUSIVE LICENSE AGREEMENT between Vir Biotechnology, Inc. and The Rockefeller UniversityExclusive License Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This Exclusive License Agreement (this “Agreement”) is by and between The Rockefeller University, a New York not-for-profit education corporation, with a principal place of business at 1230 York Avenue, New York, NY 10065 (“Rockefeller”, also referred to herein as “Licensor”) and Vir Biotechnology, Inc. a Delaware corporation, with a principal place of business at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (referred to herein as “Licensee”). This Agreement will become effective on July 31, 2018 (the “Effective Date”).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. September 7, 2018 Eric Victory Vice President & Head...Vir Biotechnology, Inc. • August 7th, 2019 • Biological products, (no disgnostic substances)
As you know, Humabs Biomed SA (“Humabs”), a wholly owned subsidiary of Vir Biotechnology Inc., and MedImmune, LLC (“MedImmune”) are parties to that certain Sub-Licence and Collaboration Agreement dated March 20, 2012, as amended (the “Agreement”). By this letter amendment (this “Amendment”), Humabs and MedImmune agree to amend the Agreement as described below, effective as of the date first set forth above.
AMENDMENT 5 TO SUB-LICENSE AND COLLABORATION AGREEMENTSub-License and Collaboration Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances)
This Amendment 5 (the “Amendment”) to the Sub-Licence and Collaboration Agreement dated March 20, 2012, as amended, (the “2012 Agreement”) is entered into and effective as of the last date of signature (the “Amendment Effective Date”), by and between:
EXCLUSIVE LICENSE AGREEMENT BETWEEN THE INSTITUTE FOR RESEARCH IN BIOMEDICINE AND HUMABS BIOMED SA, A WHOLLY-OWNED SUBSIDIARY OF HUMABS, LLCVir Biotechnology, Inc. • August 7th, 2019 • Biological products, (no disgnostic substances)
This Agreement, effective as of this December 16, 2011, is by and between the Institute for Research in Biomedicine (“IRB”), with an address at Via Vincenzo Vela 6, CH-6500 Bellinzona, Switzerland and Humabs Biomed SA, with an address at via Murate 5a, 6500 Bellinzona (“Humabs” or “Licensee”) which is a wholly-owned subsidiary of Humabs Holding GmbH (“Humabs Parent”), a Swiss limited liability company with an address at c/o Risk-Consult AG, Poststrasse 22, 6300 Zug, Switzerland.
